HIGHLIGHTS
- who: Francesca Castagnoli and colleagues from the Institute of Cancer Research, Sutton, United Kingdom, Lung Unit, Royal Marsden Hospital/Institute of have published the research work: Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy, in the Journal: PLOS ONE
- what: The aim of this study was to investigate whether changes in splenic volume could be observed in those showing clinical benefit versus those not showing clinical benefit to pembrolizumab treatment in nonsmall cell lung cancer (NSCLC) patients.
- how: In this study 70 patients . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.